More information from DoHAC and TGA
Updates on the influenza program, medicines repurposing program, and a SSSI for gliclazide are provided.
The AMA has been asked to update AMA members on the following:
Professor Paul Kelly has provided advice on the 2024 seasonal influenza vaccination under the National Immunisation Program (NIP). For all of the latest advice and resources visit the department’s dedicated influenza website.
The Australian Government Department of Health and Aged Care has commenced a new Medicines Repurposing Program (MRP) to expand treatment options and improve health outcomes for Australians.
The MRP will identify new uses for existing medicines registered on the Australian Register of Therapeutic Goods (ARTG). It aims to facilitate and encourage the ARTG registration and consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for listings on the Pharmaceutical Benefits Scheme (PBS).
More information on the Medicines Repurposing Program is available on the TGA website.
The Therapeutic Goods (Serious Scarcity and Substitutable Medicine) (Gliclazide) Instrument 2024 has been registered and is now in force until 31st July 2024.
The TGA has published a web alert about the SSSI and an About the shortage of gliclazide 30 mg tablets webpage to provide information to patients, carers and health professionals.
The substitution has PBS subsidy arrangements, and the PBS website has been updated with this information.
